Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2006

Lexicon Genetics Grant Extended by One-Year to Study Spinal Muscular Atrophy

  • Lexicon Genetics research program to identify targets for development of drugs to prevent or treat spinal muscular atrophy (SMA) has been extended for an additional year by the United States Army Medical Research & Materiel Command. Lexicon will receive $2.5 million for the one-year extension. The initial award was $2 million.

    "We believe our target discovery system uniquely positions us to find genes that may be relevant to the treatment of spinal muscular atrophy and other neurodegenerative diseases," asserts Brian P. Zambrowicz, Ph.D., executive vp of research.

    Lexicon also has an agreement with the SMA Foundation for the potential development of drugs based the results of this program.

    The SMA Foundation estimates that there are currently over 50,000 people suffering from SMA in the U.S., Europe, and Japan.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »